Saregama India Limited
Momentum (99/100) does the heavy lifting; valuation (9/100) is the drag.
ExpensiveOvervaluedSaregama India Limited earns a Hold from StocksWizard, with a blended score of 45/100. At ₹522.85 it trades above our blended DCF and relative-multiples fair value of ₹361.82, about 31% downside to that estimate — we read it as overvalued by 31%. On 43.8x trailing earnings it sits pricier than the Communication Services median of about 25.0x. It's trading right at its 52-week high of ₹530.45. Financial health scores 100/100, in the safe band on the Altman Z-score, with a Piotroski F-score of 3/9. The average analyst target of ₹507 implies about 3% downside across 4 analysts. It clears 9 of 13 investability checks, with durability 77, valuation 17 and momentum 99 on our 0–100 scales.
Analysis by Ankit Sharma · StocksWizard's own estimates from end-of-day public data — see how we calculate them. For information only, not investment advice.
With a 20% margin of safety, our buy-below price is ₹289.46.
Analyst views
1-year price
EOD · 2026-07-3152-week range
-1.43% from the 52-week high.
Price above both moving averages reads as an intact uptrend; below both, the trend is against you.
Verdict pillars
Hold45Piotroski F-score 3/9 — quality of earnings & balance sheet.
Our scores
Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.
Investability checklist
- Fail: ROE above 15%: 12.6%
- Pass: Low debt (D/E < 0.5): 0.04x
- Pass: Positive free cash flow
- Pass: Revenue growth > 10%: 19%
- Pass: Earnings growing: 24%
- Pass: Net margin ≥ 10%: 21.0%
- Pass: Current ratio > 1.5: 1.75
- Fail: Below our fair value
- Fail: Margin of safety ≥ 20%
- Pass: Above 200-day average
- Pass: Above 50-day average
- No data: Positive 1-year return
- Pass: Altman Z in safe zone: Z 9.65
- Fail: Piotroski ≥ 7: 3/9
Quarterly results
Annual financials
Shareholding
- Promoter63.6%
- Institutions11.1%
- Public & other25.4%
Promoter holding via insider stake; institutional via reported holdings.
Key fundamentals
Bull case vs bear case
Bull case
Strengths
- Lightly leveraged balance sheet.
- Healthy profit margin (21.0%).
- Trading near its 52-week high.
- Financially solid — Altman Z 9.65.
Opportunities
- Earnings growing (24% YoY).
- Revenue growing (19% YoY).
Bear case
Weaknesses
- Weak Piotroski score (3/9).
Threats
- Rich valuation versus sector peers.
- Trades ~31% above our estimated fair value.
About Saregama India Limited
Saregama India Limited is an entertainment company operating across India and internationally through four business segments: Music, Artist Management, Video, and Events. Its Music segment manufactures and sells music storage devices including Carvaan and Music Cards, vinyl records, and manages associated music rights.
Saregama India Limited — frequently asked questions
Is Saregama India Limited a buy, hold or sell?
StocksWizard currently rates Saregama India Limited (SAREGAMA) a Hold, based on a blended score of 45/100 across valuation, quality, momentum and price trend. This is our own model-based view, not investment advice.
What is Saregama India Limited's fair value?
Our blended DCF and relative-valuation model estimates Saregama India Limited's fair value at about ₹361.82, versus a current price of ₹522.85 — roughly 31% downside. On that basis the stock looks overvalued by 31%.
Is Saregama India Limited financially healthy?
Saregama India Limited scores 100/100 on our financial-health model, placing it in the safe band on the Altman Z-score, with a Piotroski F-score of 3/9.
How has Saregama India Limited's share price performed?
Saregama India Limited is up 52% over three months, and last traded at ₹522.85. Past performance doesn't predict future returns.
More in Communication Services
View allOur verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.